Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 20/20 | 0.54 |
| ▸ | FNTB | P49356 | 15/20 | 0.54 |
| ▸ | PGGT1B | P53609 | 17/20 | 0.52 |
| ▸ | NRAS | P01111 | 1/20 | 0.47 |
| ▸ | HRAS | P01112 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7168234 | 0.95 | FNTA (0.54) | FNTAFNTBPGGT1BNRASHRAS | |
| Trifluoroacetic Acid SCHEMBL7166202 | 0.90 | FNTA (0.52) | FNTAFNTBPGGT1BNRASHRAS | |
| SCHEMBL6523879 | 0.87 | FNTA (0.62) | FNTAFNTBPGGT1BNRASHRAS | |
| SCHEMBL7161938 | 0.84 | FNTA (0.56) | FNTAFNTBPGGT1BNRASHRAS | |
| Trifluoroacetic Acid SCHEMBL7168232 | 0.84 | FNTA (0.52) | FNTAFNTBPGGT1BNRASHRAS | |
| SCHEMBL7165178 | 0.82 | FNTA (0.62) | FNTAFNTBPGGT1BNRASHRAS | |
| SCHEMBL6430353 | 0.81 | FNTA (0.48) | FNTAFNTBPGGT1BNRASHRAS | |
| SCHEMBL7167596 | 0.81 | FNTA (0.56) | FNTAFNTBPGGT1BNRASHRAS | |
| SCHEMBL31471961 | 0.79 | FNTA (0.67) | FNTAFNTBPGGT1BNRASHRAS | |
| SCHEMBL6412093 | 0.78 | FNTA (0.35) | FNTAFNTBPGGT1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030220241-A1 | Method of treating cancer | DEFEO-JONES DEBORAH (US) | 2003-11-27 | — | — | US | disclosed |
| US-6562823-B1 | Inhibition of farnesyl-protein transferase has been shown to block the growth of Ras-transformed cells in soft agar | MERCK & CO., INC. | 2003-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220241-A1 | Method of treating cancer | ACP3, PSAT1, LCAT | FNTA 4/4885FNTB 19/4885PGGT1B 274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.